Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple supplement slow Alzheimer's? new trial aims to find out

NCT ID NCT07062198

Disease control Sponsor: ScandiBio Therapeutics AB Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a combination of four natural substances (CMA2) can improve brain function in people with Alzheimer's disease. About 845 adults aged 50 and older will take either the supplement or a placebo twice daily for 26 weeks. Researchers will measure changes in memory and thinking skills using standard tests to see if the supplement slows the disease's progression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 845 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Men and women of non-childbearing potential ≥ 50 years of age. 2. Diagnosed with AD and at the Screening visit having the scores of ADAS-Cog ≥ 12 and GDS≥ 4. 3. Stable AD treatments and clinical course for at least 1 month. 4. Females of childbearing potential must have documented tubal ligation or hysterectomy; or be post-menopausal (defined as 12 months of amenorrhoea \[in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) 25-140 IE/L and oestradiol \<200 pmol/Lis confirmatory\]). 5. Able to give written informed consent for participation in the study by the patient and/or legal representatives. Exclusion Criteria: 1. History of stroke. 2. History of brain trauma \< 14 days. 3. Uncontrolled diagnosed depression. 4. Uncontrolled (HbA1C \> 8) type 1 or type 2 diabetes. 5. Severe swallowing problems. 6. PEG-feeding. 7. Chronic diarrhoea. 8. Chronic kidney disease with S-Creatinin \> 1,30 mg/dl. 9. Active bronchial asthma at the time of screening. 10. History of phenylketonuria (contraindicated for NAC). 11. Known allergy for substances used in the study. 12. Known malignancies. 13. Use of dietary supplements such as vitamins, omega-3 products, or plant stanol/sterol products later than one (1) week prior to inclusion. 14. Use of anti-microbial agents later than one (1) week prior to inclusion. 15. Drug and/or alcohol abuse. 16. Subjects considered as inappropriate for this study for any reason (noncompliance etc.) per investigator assessment. 17. Administration of another new chemical entity (defined as a compound that has not been approved for marketing) or has participated in any other clinical study that included drug treatment with the last administration within 3 months prior to administration of IMP in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ataturk University, Faculty of Medicine, Department of Neurology, Erzurum, Turkey; Movement Disorders and Neuromodulation Center, Ataturk University

    RECRUITING

    Erzurum, Turkey (Türkiye)

  • Behavioural Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine, Istanbul University

    RECRUITING

    Istanbul, Turkey (Türkiye)

  • Department of Neurology and Neuroscience, Faculty of Medicine, Alaaddin Keykubat University

    RECRUITING

    Alanya, Turkey (Türkiye)

  • Haydarpaşa Numune Training and Research Hospital, University of Health Sciences Istanbul

    NOT_YET_RECRUITING

    Istanbul, Turkey (Türkiye)

  • SB Haseki Training and Research Hospital, Istanbul, University of Health Sciences Istanbul

    RECRUITING

    Istanbul, Turkey (Türkiye)

  • Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, University of Health Sciences Istanbul

    RECRUITING

    Istanbul, Turkey (Türkiye)

  • Sultan Abdülhamid Han Training and Research Hospital, University of Health Sciences Istanbul

    RECRUITING

    Istanbul, Turkey (Türkiye)

  • Umraniye Training and Research Hospital, University of Health Sciences Istanbul

    RECRUITING

    Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.